OnKure Therapeutics, Inc. Class A Common Stock (OKUR)

• Market cap: $32.3M
• 1 day: -2.45%
• 5 days: -9.81%
• 1 month: -5.53%
• 3 months: -8.08%
• 6 months: -50.41%
• Year to date: -71.95%
• 1 year: -82.55%
• 5 years: -98.28%
• 10 years: -98.28%
• Sector: Healthcare
• Industry: Biotechnology

About: OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Employees: 46

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

4% more funds holding

Funds holding: 47 [Q1] → 49 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

9.63% less ownership

Funds ownership: 93.69% [Q1] → 84.06% (-9.63%) [Q2]

49% less capital invested

Capital invested by funds: $50.1M [Q1] → $25.8M (-$24.4M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $34
• Avg. target: $34
• High target: $34

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns

$34

Buy Reiterated

26 Aug 2025